NVC-422 topical gel for the treatment of impetigo

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 6, 2011, Pages 587-595

  Iovino, Susan M ^a   Krantz, Kenneth D ^a   Blanco, Daisy M ^b   Fernández, Josefina A ^c   Ocampo, Naomi ^a   Najafi, Azar ^a   Memarzadeh, Bahram ^a   Celeri, Chris ^a   Debabov, Dmitri ^a   Khosrovi, Behzad ^a   Anderson, Mark ^a  

^a NovaBay Pharmaceuticals Inc   (United States)

^b Dirección Nacional de Control de Infecciones de Transmisión Sexual y SIDA   (Dominican Republic)

^c School of Medicine   (Dominican Republic)

Author keywords

Clinical phase 2; Impetigo; Mrsa; NVC 422; Staphylococcus; Streptococcus

Indexed keywords

ANTIINFECTIVE AGENT; DRUG DERIVATIVE; NVC 422; NVC-422; TAURINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HUMAN; IMPETIGO; INTENTION TO TREAT ANALYSIS; ISOLATION AND PURIFICATION; MALE; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SKIN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; IMPETIGO; INTENTION TO TREAT ANALYSIS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; SKIN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TAURINE; TREATMENT OUTCOME;

EID: 80054774111     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Koning S, Verhagen AP, van Suijlekom-Smit LWA, Morris AD, Butler C, van der Wouden JC. Interventions for impetigo. Cochrane Database of Systematic Reviews 2004; Issue 2. Art. N o: CD003261. DOI: 10.1002/14651858.CD003261.pub2
2. Rørtveit S, Rørtveit G, Impetigo in epidemic and non-epidemic phases: An incidence study over years in general population. Br J Dermatol 2007; 157: 100-105.
3. Steer AC, Jenney AWJ, Kado J, Batzloff MR, La Vincente S. High Burden of Impetigo and Scabies in a Tropical Country. PLoS Negl Trop Dis 2009; 3: e467.
4. Ferrieri, P, Dajani, AS, Wannamaker, LW. Natural History of Impetigo. I. Site sequence of acquisition and familial patterns of spread of coetaneous streptococci. J Clin Invest 1972; 51: 2851-2862.
5. Bisno AL, Stevens DL: Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334: 240-245.
6. Epstein, S. Staphylococcic Impetigo Contagiosa. Arch Derm Syphilol 1940; 42: 840-855.
7. Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 2005; 11: 928-930.
8. Hayward A, Knott F, Petersen I, Livermore DM, Duckworth G, Islam A, Johnson AM. Increasing Hospitalizations and General Practice Prescriptions for Community-onset Staphylococcal Disease, England. Emerg Infect Dis 2008; 14: 720-726.
9. Edelsberg J, Taneja C, Zervos M, Haque N, Moore C, Reyes K, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009; Sep Available from http://www.cdc.gov/EID/content/15/9/1516.htm. DOI: 10.3201/ eid1509.081228.
10. Cohen PR, Community-acquired methicillinresistant Staphylococcus aureus skin infections: a review of epidemiology, clinical features, management, and prevention. Int J Dermatol 2007; 46: 1-11.
11. Durupt F, Mayor L, Bes M. Prevalence of Staphylococcus aureus toxins and nasal carriage in furuncles and impetigo. Br J Dermatol 2007; 157: 1161-1167.
12. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin Resistance. Clin Infect Dis 2009; 49(6): 935-941.
13. Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 1998; 41: 11-18.
14. Dobie D, Gray J. Fusidic acid resistance in Staphylococcus aureus. Arch Dis Child 2004; 89: 74-77.
15. Rørtveit S, Skutlaberg DH, Langeland N, Rortveit G. Impetigo in a population over 8.5 years: incidence, fusidic acid resistance and molecular characteristics. J Antimicrob Chemother 2011; 66: 1360-1364.
16. Alsterholm M, Flytström I, Bergbrant IM, Faergemann J. Fusidic acid-resistant Staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis. Acta Derm Venereol 2010; 90: 52-57.
17. Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1992; 36: 287-290.
18. Yang LP, Keam SJ. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 2008; 68: 855-873.
19. Farrell DJ, Robbins M, Rhys-Williams W, Love WG. Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study. Antimicrob Agents Chemother 2011; 55: 1177-1181.
20. Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother 2003; 51: 613-617.
21. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin Resistance. Clin Infect Dis 2009; 49: 935-941.
22. Dobie D, Gray J. Fusidic acid resistance in Staphylococcus aureus. Arch Dis Child 2004; 89: 74-77.
23. Katopodis GD, Grivea IN, Tsantsaridou AJ, Pournaras S, Petinaki E, Syrogiannopoulos GA. Fusidic acid and clindamycin resistance in community-associated, methicillin-resistant Staphylococcus aureus infections in children of Central Greece. BMC Infect Dis 2010; 10: 351.
24. Wang L, Belisle, B, Bassiri M, Xu P, Debabov D, Celeri C, Alvarez N, Robson MC, Payne WG, Najafi R, Khosrovi B. Chemical Characterization and Biological Properties of NVC-422, a Novel, Stable N-Chlorotaurine Analog. Antimicrob Agents Chemother 2011; 55: 2688-2692.
25. FDA Briefing Document for Anti-Infective Drugs Advisory Committee Meeting, November 18, 2008 Justification for the Non-Inferiority Margin for the Treatment of complicated Skin and Skin Structure Infections
26. The Division of Anti-Infective and Ophthalmology Products and the Division of Special Pathogen and Transplant Products in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration; Guidance for Industry: Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment; U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 2010.